🦠 Mast Cell Activation Syndrome Simulator

Baseline Mast Cell Distribution Across the Body

Mast cells sit ready in skin, gut, and vessels, normal threshold.

• Skin/Gut/Vessels: Tissue sites (placeholder distribution)
• Normal: Activation threshold (placeholder baseline)
• Not required: IgE pathway (non-allergic mechanism)
• 0: Symptom systems (placeholder baseline count)

Mast cells as tissue-resident sentinels

Placeholder: mast cells reside widely, poised but quiescent normally.

Normal activation threshold

Placeholder: everyday stimuli stay below the firing threshold.

Post-COVID Mast Cells Become Hyperreactive

Non-specific triggers like heat or stress now provoke activation.

• Non-IgE: Mechanism (no allergen cross-linking)
• Heat/Stress/Exercise: Trigger types (placeholder examples)
• Lowered: Threshold shift (placeholder direction)
• Post-COVID: Onset context (placeholder timing)

Non-allergic trigger pathways

Placeholder: viral aftermath sensitizes mast cells to ordinary stimuli.

Idiopathic hyperactivation

Placeholder: no specific allergen is identifiable in most cases.

Diffuse Mediator Release Across Organ Systems

Histamine and tryptase release simultaneously in several tissues.

• Histamine: Mediator 1 (placeholder mediator)
• Tryptase: Mediator 2 (placeholder mediator)
• Diffuse: Release pattern (multi-site, not local)
• Dose-linked: Trigger dependence (placeholder relation)

Widespread degranulation

Placeholder: mediators escape from mast cells across body regions.

Dose-dependent trigger response

Placeholder: higher trigger exposure yields more mediator release.

Symptoms Emerge Across Multiple Body Systems

Flushing, GI upset, tachycardia, and brain fog appear together.

• Flushing: Skin (placeholder symptom)
• Cramping/diarrhea: GI (placeholder symptom)
• Tachycardia: Cardiac (placeholder symptom)
• Brain fog: Neuro (placeholder symptom)

Wide symptom footprint

Placeholder: distribution of mast cells explains scattered symptoms.

Overlap with Long COVID picture

Placeholder: MCAS symptoms mirror many reported Long COVID complaints.

Blockade and Stabilization Reduce Mediator Burden

H1/H2 blockers and cromolyn sodium calm mast cell output.

• Antihistamine: H1 blocker (placeholder class)
• Antihistamine: H2 blocker (placeholder class)
• Cromolyn sodium: Stabilizer (placeholder mechanism)
• Reduced release: Combined effect (placeholder outcome)

Receptor blockade

Placeholder: H1/H2 blockers reduce downstream histamine effects.

Membrane stabilization

Placeholder: cromolyn limits degranulation at the source.

Placeholder: combined blockade and stabilization lowers symptom burden most.